Excellent Prognosis - Standard Risk Multiple Myeloma
A patient with multiple myeloma who has normal cytogenetics, normal FISH, no TP53 mutation, and is amyloid negative has standard-risk disease with an excellent prognosis, representing the most favorable risk category in the 2025 International Myeloma Society/International Myeloma Working Group risk stratification. 1, 2
Risk Stratification Framework
Your patient's profile places them in the standard-risk category based on the absence of all high-risk cytogenetic abnormalities. The 2025 IMS/IMWG consensus specifically defines high-risk multiple myeloma by the presence of:
- del(17p) with cancer clonal fraction ≥20% on CD138+ cells
- TP53 mutations detected by NGS on CD138+ cells
- t(14;16) translocation
- t(14;20) translocation
- Gain/amplification of 1q21 (particularly when co-occurring with other abnormalities)
- del(1p32) 1
Since your patient has none of these features, they fall into the most favorable prognostic group.
Expected Survival Outcomes
Based on the guideline evidence, patients without high-risk cytogenetic abnormalities demonstrate:
- Median progression-free survival (PFS): 39-51 months with modern therapy 1, 3
- Median overall survival (OS): 99-107 months (over 8 years) 1, 3
This contrasts sharply with high-risk patients who have del(17p) or TP53 mutations, where median OS drops to 13.9-38.7 months 4.
Clinical Implications
The absence of TP53 abnormalities is particularly significant. The 2025 guidelines emphasize that TP53 dysregulation—whether through del(17p) or mutation—represents one of the most powerful independent adverse prognostic factors 1. Your patient's normal TP53 status by both FISH and mutation testing provides strong reassurance.
The amyloid-negative status further improves prognosis by eliminating organ dysfunction complications that would otherwise compromise quality of life and treatment tolerance.
Treatment Response Expectations
Patients with standard-risk cytogenetics typically achieve:
- Higher deep response rates (complete response + very good partial response) to standard induction therapy with bortezomib, lenalidomide, and dexamethasone (VRd) 5
- Better treatment tolerance without the aggressive tumor biology seen in high-risk disease 5
- Lower risk of early progression compared to those with cytogenetic abnormalities 3
Important Monitoring Considerations
Serial cytogenetic monitoring during follow-up is critical, even in standard-risk patients. The evidence shows that:
- 49% of patients may acquire de novo FISH abnormalities during disease course 3
- Acquiring ≥2 new abnormalities significantly worsens PFS (median 24 vs. 45 months) 3
- New abnormalities appearing within 31 months of diagnosis confer particularly poor outcomes 3
Recommendation: Repeat FISH testing at disease progression or relapse, as clonal evolution can change risk stratification and treatment strategy 3.
Pitfalls to Avoid
- Do not assume standard risk remains static: Cytogenetic evolution occurs in approximately half of patients during follow-up 3
- Ensure proper testing methodology: The normal FISH results should have been performed on CD138+ enriched plasma cells, as non-enriched samples may miss abnormalities 2
- Consider comprehensive FISH panels: The standard panel should include all high-risk markers (del(17p), t(4;14), t(14;16), 1q21 gain, 1p32 deletion) 1, 2
Bottom Line
Your patient represents the best-case scenario in multiple myeloma risk stratification. With modern therapy, they can expect prolonged survival exceeding 8 years and high likelihood of achieving deep treatment responses. The key is maintaining vigilance through serial cytogenetic monitoring to detect any clonal evolution that would warrant treatment modification.